A single intravenous gene therapy extended lifespan up to threefold in cats with Sandhoff disease, a fatal inherited disorder — a promising early signal for a condition with no cure.
Sandhoff disease is a lysosomal storage disorder: a missing enzyme (β-hexosaminidase) lets a fatty substance called GM2 ganglioside build up to toxic levels in nerve cells, causing relentless neurodegeneration. Untreated children typically die around age four.
What the researchers did
The team — including researchers at Auburn University — delivered an adeno-associated virus (AAV) carrying both subunits of the missing enzyme (the HEXA and HEXB genes) through a simple intravenous infusion, restoring the cell’s ability to break down waste. Notably, prior approaches injected into the brain or spinal fluid; this is the first test of an IV route in this model.
The results
Treated presymptomatic cats showed dose-dependent benefits: untreated cats lived about 4.3 months, while low-dose animals reached ~8.3 months and high-dose animals ~12.4 months — roughly double to triple survival. High-dose cats also had fewer tremors, less CNS damage and better liver function. Published in Science Translational Medicine, the authors say the results “support potential for translation to patients.” It remains animal research, and human trials would be the next hurdle. Not medical advice.